SecBot SecBot
SECBOTREPLAY Home › Report › SION

SION · GS discloses 5.8% passive stake

Sionna Therapeutics, Inc. · SC 13G filed Nov 9, 2026 at 14:24 ET

At the news

NEUTRALIMPACT 3/10

SC 13G filed Nov 9, 2026 at 14:24 ET

Goldman Sachs Group and its subsidiary Goldman Sachs & Co. LLC disclosed a 5.8% passive stake in Sionna Therapeutics via a Schedule 13G filing. The stake of 2,639,418 shares was held as of September 30, 2026, and the filing certifies passive intent with no aim to influence control.

  • Goldman Sachs Group and Goldman Sachs & Co. LLC filed a Schedule 13G disclosing beneficial ownership of 2,639,418 shares of Sionna Therapeutics common stock.
  • The stake represents 5.8% of shares outstanding as of September 30, 2026.
  • The filing certifies the securities were acquired and held in the ordinary course of business, not to change or influence control.
  • This is a new 13G filing by Goldman Sachs; no prior 13G from this filer appears in the cross-filing context.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access